Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10

Rile Li, Kateri Heydon, M. Elizabeth Hammond, David J. Grignon, Mack Roach, Harvey B. Wolkov, Howard M. Sandler, William U. Shipley, Alan Pollack

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: Proliferative activity defined by Ki-67 staining index (SI) has been correlated with progression and prognosis in a number of malignant tumors including prostate cancer. However, few studies have examined Ki-67 SI in pretreatment diagnostic material from patients treated with definitive radiotherapy. In a prior study, we found that a Ki-67 SI of >3.5% was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point. Experimental Design: Of 456 assessable patients in Radiation Therapy Oncology Group Protocol 86-10, diagnostic material from 108 patients was available for Ki-67 analysis using MIB-1 antibody. Sixty patients were treated with external beam radiotherapy (EBRT) alone, and 48 patients were treated with short-term androgen deprivation + EBRT. Median follow-up was 9 years for those living. The relationship of Ki-67 with distant metastasis (DM), disease-specific survival (DSS), and overall survival (OS) was examined. Results: The median Ki-67 SI was 7.1% (range, 0.2-45.5%). The 7.1% cut point was associated with DM and DSS; however, the 3.5% cut point was as strong a determinant and was the focus of this analysis. In Cox proportional hazards regression, Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was ≤3.5% and >3.5%, the 5-year risk of DM was 13.5% and 50.8% (P = 0.0005), respectively, and the 5-year risk of DSS was 97.3% and 67.7% (P = 0.0039), respectively. No association of Ki-67 SI with OS was observed. Conclusions: Higher Ki-67 SI was significantly associated with a greater risk of DM and DSS in locally advanced prostate cancer after definitive EBRT or AD + EBRT.

Original languageEnglish
Pages (from-to)4118-4124
Number of pages7
JournalClinical Cancer Research
Volume10
Issue number12 I
DOIs
StatePublished - Jul 15 2004
Externally publishedYes

Fingerprint

Radiation Oncology
Prostatic Neoplasms
Radiotherapy
Staining and Labeling
Neoplasm Metastasis
Survival
Androgens
Research Design

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy : An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. / Li, Rile; Heydon, Kateri; Hammond, M. Elizabeth; Grignon, David J.; Roach, Mack; Wolkov, Harvey B.; Sandler, Howard M.; Shipley, William U.; Pollack, Alan.

In: Clinical Cancer Research, Vol. 10, No. 12 I, 15.07.2004, p. 4118-4124.

Research output: Contribution to journalArticle

Li, Rile ; Heydon, Kateri ; Hammond, M. Elizabeth ; Grignon, David J. ; Roach, Mack ; Wolkov, Harvey B. ; Sandler, Howard M. ; Shipley, William U. ; Pollack, Alan. / Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy : An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 12 I. pp. 4118-4124.
@article{bb8173f210d146b7bb7f32614b31bfa6,
title = "Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10",
abstract = "Purpose: Proliferative activity defined by Ki-67 staining index (SI) has been correlated with progression and prognosis in a number of malignant tumors including prostate cancer. However, few studies have examined Ki-67 SI in pretreatment diagnostic material from patients treated with definitive radiotherapy. In a prior study, we found that a Ki-67 SI of >3.5{\%} was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point. Experimental Design: Of 456 assessable patients in Radiation Therapy Oncology Group Protocol 86-10, diagnostic material from 108 patients was available for Ki-67 analysis using MIB-1 antibody. Sixty patients were treated with external beam radiotherapy (EBRT) alone, and 48 patients were treated with short-term androgen deprivation + EBRT. Median follow-up was 9 years for those living. The relationship of Ki-67 with distant metastasis (DM), disease-specific survival (DSS), and overall survival (OS) was examined. Results: The median Ki-67 SI was 7.1{\%} (range, 0.2-45.5{\%}). The 7.1{\%} cut point was associated with DM and DSS; however, the 3.5{\%} cut point was as strong a determinant and was the focus of this analysis. In Cox proportional hazards regression, Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was ≤3.5{\%} and >3.5{\%}, the 5-year risk of DM was 13.5{\%} and 50.8{\%} (P = 0.0005), respectively, and the 5-year risk of DSS was 97.3{\%} and 67.7{\%} (P = 0.0039), respectively. No association of Ki-67 SI with OS was observed. Conclusions: Higher Ki-67 SI was significantly associated with a greater risk of DM and DSS in locally advanced prostate cancer after definitive EBRT or AD + EBRT.",
author = "Rile Li and Kateri Heydon and Hammond, {M. Elizabeth} and Grignon, {David J.} and Mack Roach and Wolkov, {Harvey B.} and Sandler, {Howard M.} and Shipley, {William U.} and Alan Pollack",
year = "2004",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-1052-03",
language = "English",
volume = "10",
pages = "4118--4124",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12 I",

}

TY - JOUR

T1 - Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy

T2 - An analysis of patients in Radiation Therapy Oncology Group Protocol 86-10

AU - Li, Rile

AU - Heydon, Kateri

AU - Hammond, M. Elizabeth

AU - Grignon, David J.

AU - Roach, Mack

AU - Wolkov, Harvey B.

AU - Sandler, Howard M.

AU - Shipley, William U.

AU - Pollack, Alan

PY - 2004/7/15

Y1 - 2004/7/15

N2 - Purpose: Proliferative activity defined by Ki-67 staining index (SI) has been correlated with progression and prognosis in a number of malignant tumors including prostate cancer. However, few studies have examined Ki-67 SI in pretreatment diagnostic material from patients treated with definitive radiotherapy. In a prior study, we found that a Ki-67 SI of >3.5% was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point. Experimental Design: Of 456 assessable patients in Radiation Therapy Oncology Group Protocol 86-10, diagnostic material from 108 patients was available for Ki-67 analysis using MIB-1 antibody. Sixty patients were treated with external beam radiotherapy (EBRT) alone, and 48 patients were treated with short-term androgen deprivation + EBRT. Median follow-up was 9 years for those living. The relationship of Ki-67 with distant metastasis (DM), disease-specific survival (DSS), and overall survival (OS) was examined. Results: The median Ki-67 SI was 7.1% (range, 0.2-45.5%). The 7.1% cut point was associated with DM and DSS; however, the 3.5% cut point was as strong a determinant and was the focus of this analysis. In Cox proportional hazards regression, Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was ≤3.5% and >3.5%, the 5-year risk of DM was 13.5% and 50.8% (P = 0.0005), respectively, and the 5-year risk of DSS was 97.3% and 67.7% (P = 0.0039), respectively. No association of Ki-67 SI with OS was observed. Conclusions: Higher Ki-67 SI was significantly associated with a greater risk of DM and DSS in locally advanced prostate cancer after definitive EBRT or AD + EBRT.

AB - Purpose: Proliferative activity defined by Ki-67 staining index (SI) has been correlated with progression and prognosis in a number of malignant tumors including prostate cancer. However, few studies have examined Ki-67 SI in pretreatment diagnostic material from patients treated with definitive radiotherapy. In a prior study, we found that a Ki-67 SI of >3.5% was associated with poorer patient outcome. The goals of this analysis were to validate the prognostic value of Ki-67 SI and this cut point. Experimental Design: Of 456 assessable patients in Radiation Therapy Oncology Group Protocol 86-10, diagnostic material from 108 patients was available for Ki-67 analysis using MIB-1 antibody. Sixty patients were treated with external beam radiotherapy (EBRT) alone, and 48 patients were treated with short-term androgen deprivation + EBRT. Median follow-up was 9 years for those living. The relationship of Ki-67 with distant metastasis (DM), disease-specific survival (DSS), and overall survival (OS) was examined. Results: The median Ki-67 SI was 7.1% (range, 0.2-45.5%). The 7.1% cut point was associated with DM and DSS; however, the 3.5% cut point was as strong a determinant and was the focus of this analysis. In Cox proportional hazards regression, Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was independently associated with DM and DSS. When the Ki-67 SI was ≤3.5% and >3.5%, the 5-year risk of DM was 13.5% and 50.8% (P = 0.0005), respectively, and the 5-year risk of DSS was 97.3% and 67.7% (P = 0.0039), respectively. No association of Ki-67 SI with OS was observed. Conclusions: Higher Ki-67 SI was significantly associated with a greater risk of DM and DSS in locally advanced prostate cancer after definitive EBRT or AD + EBRT.

UR - http://www.scopus.com/inward/record.url?scp=3042663353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042663353&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-1052-03

DO - 10.1158/1078-0432.CCR-1052-03

M3 - Article

C2 - 15217948

AN - SCOPUS:3042663353

VL - 10

SP - 4118

EP - 4124

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12 I

ER -